Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes, including a five-year survival of below 10%. Poor outcomes result in part from therapeutic resistance that limits the impact of cytotoxic first-line therapy. Novel therapeutic approaches are needed, but currently no t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaker, Ryne C., Hardigan, Andrew A., Gordon, Emily R., Wright, Carter A., Myers, Richard M., Cooper, Sara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164247/
https://www.ncbi.nlm.nih.gov/pubmed/34049503
http://dx.doi.org/10.1186/s12885-021-08388-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164247/
https://www.ncbi.nlm.nih.gov/pubmed/34049503
http://dx.doi.org/10.1186/s12885-021-08388-1

Ejemplares similares